Mercury Laboratories Ltd (538964)
🎯 Key Takeaways
- Mercury Laboratories Ltd appears to be a mature, cash-generating pharmaceutical company operating in a highly regulated segment with stable promoter ownership. Despite flat revenue trends and volatile profitability, the business maintains positive cash flows from operations and a pristine balance sheet with negligible debt.
- Revenue declined 21.9% QoQ to ₹16 in Q1FY27.
- ⚠️ Persistent margin compression in the latest quarter, with OPM falling to 2.9%, raises concerns about pricing pressure or input cost increases not yet
📖 The Story
Mercury Laboratories Ltd appears to be a mature, cash-generating pharmaceutical company operating in a highly regulated segment with stable promoter ownership. Despite flat revenue trends and volatile profitability, the business maintains positive cash flows from operations and a pristine balance sheet with negligible debt. The company is likely in a consolidation or maintenance phase rather than aggressive growth, with management focusing on operational efficiency and capital preservation.
📰 What's Happening
Management has not announced any new capacity expansions or major product launches in the latest filings. The consistent promoter holding at 73.66% across all recent quarters suggests no strategic divestment or restructuring is underway. There are no indications of acquisitions or joint ventures in the disclosed events. The company continues to operate with a lean balance sheet, maintaining minimal working capital requirements typical of niche API and formulation manufacturers.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 19 | 18 | 20 | 16 |
| Operating Profit | 1 | 2 | 1 | 0 |
| OPM % | 6.6% | 9.0% | 5.9% | 2.9% |
| Net Profit | 2 | 1 | 1 | 0 |
| EPS | ₹13.69 | ₹8.31 | ₹10.21 | ₹2.48 |
Revenue has remained largely flat over the past four quarters, hovering between ₹16–20 crore with no clear upward trend. Operating profitability has shown mixed results, with OPM declining from 9% in December 2025 to 2.9% in June 2026, despite stable top-line levels. Net profits have been erratic, turning negative in the most recent quarter, though annualized figures suggest underlying stability. The volatility in margins and earnings appears to reflect seasonal or operational fluctuations rather than structural deterioration, though the downward margin trend in the latest quarter warrants monitoring.
🔮 Management Outlook & What's Next
There is no explicit forward guidance or strategic outlook provided in the latest regulatory filings. Management commentary focuses on operational continuity rather than future growth targets or market expansion plans. The absence of new product launches, capacity additions, or market development initiatives suggests a conservative, status-quo approach to business operations in the near term.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 |
| Reserves | 51 | 52 | 55 | 57 |
| Borrowings | 5 | 4 | 6 | 8 |
| Total Liabilities | 69 | 74 | 74 | 79 |
| Fixed Assets | 25 | 25 | 24 | 24 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 69 | 74 | 74 | 79 |
The balance sheet remains extremely conservative, with equity and reserves growing slightly while borrowings remain trivial at ₹8 lakh as of March 2026. Total assets have increased modestly, indicating minimal capital expenditure or strategic investment. The company is not leveraging its balance sheet for growth, and the strong equity base supports financial stability without requiring external financing. This suggests a capital-light, low-risk operational model with limited reinvestment needs.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +4 |
| Investing | -9 |
| Financing | -1 |
| Net Cash Flow | -6 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 73.7% | 73.7% | 73.7% | 73.7% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 16.7% | 16.6% | 16.6% | 16.6% |
| # Shareholders | 1,365 | 1,321 | 1,316 | 1,328 |
Promoter holding remains stable at 73.66% with no changes in pledge or stake sales. Institutional ownership is effectively zero, with FII and DII holdings flat at 0% over the past year. The slight decline in public shareholding percentage (from 16.71% to 16.58%) is marginal and may reflect minor retail trading activity rather than institutional exit. The shareholder base is highly concentrated and passive, with no signs of activist involvement or significant investor churn.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.69 L Cr | 38.8 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.45 L Cr | 83.9 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.4 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.14 L Cr | 33.9 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.03 L Cr | 94.1 | 20.8% | 20.6% | 0.45 |
| LUPIN | 99,585 | 17.6 | 27.9% | 24.7% | 0.26 |
| MANKIND | 99,078 | 48.5 | 13.9% | 12.7% | 0.38 |
| DRREDDY | 97,240 | 30.1 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 97,239 | 26.4 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent margin compression in the latest quarter, with OPM falling to 2.9%, raises concerns about pricing pressure or input cost increases not yet offset by scale or efficiency gains. 2. Net loss in the most recent quarter (₹0) despite revenue stability suggests vulnerability to cost volatility or operational disruptions. 3. Heavy reliance on a concentrated product portfolio or limited customer base could expose the company to regulatory or supply chain risks, though this is not explicitly disclosed. 4. Lack of growth initiatives or new product pipelines may lead to long-term stagnation if core markets saturate or face pricing erosion.
🧠 Analyst's Read
Mercury Laboratories operates as a stable but stagnant player in the pharmaceutical space, with financial resilience offset by limited growth catalysts. Investors should monitor margin recovery in upcoming quarters and any shift in management's strategic tone, particularly around product diversification or export expansion. The absence of institutional interest and flat promoter holding suggests limited upside potential in the near term, making the stock sensitive to sector-specific headwinds rather than company-specific catalysts.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd